We are monitoring the impact of COVID-19 on Europe Biopharmaceutical Contract Manufacturing Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 7601
Share on
Share on

Europe Biopharmaceutical Contract Manufacturing Market Research Report - Segmented By Product Type, Therapeutic Area, Application & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Share, Size, Trends, Growth, & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 7601
Pages: 145

Europe Biopharmaceutical Contract Manufacturing Market Size & Growth (2021 to 2026):

As per the research report, the size of the Europe Biopharmaceutical Contract Manufacturing market is valued at USD 1.64 billion in 2021. It is expected to rise at a CAGR of 9.3% capping the market to USD 2.56 billion by 2026 during the forecast period 2021 to 2026.

Biopharmaceuticals are biological products that are made and developed to help with illness prevention and treatment. Recent advances in bio manufacturing and biotechnology have sparked the development of novel technologies capable of tackling the challenges associated with the production of biopharmaceuticals. As a result, the biopharmaceuticals contract manufacturing market is expanding.

The biopharmaceutical contract manufacturing market is primarily driven by the faster pace of production with contract manufacturing organizations, less cost than own manufacturing facilities, entry-level pharmaceutical production enterprises searching for investors. Furthermore, faster approvals for patent sharing, intellectual property copyright rules, higher demand for drugs by people, lower production capacity, and other factors are expected to boost the growth rate of the biopharmaceutical contract manufacturing industry. Instead of manufacturing every drug independently, they opt for contractual obligations with small companies to produce medicines through MOUs or investments.

Pharmaceutical companies see this as an opportunity to decrease their manufacturing costs by outsourcing these functions. As a result, production costs can be shifted to the research and development division, allowing for more efficient discoveries. Moreover, the rise of the biopharmaceutical contract manufacturing business presents an opportunity for CMOs in the form of mergers, acquisitions, and joint ventures with large corporations. These initiatives help CMOs see the possibilities for making their companies more financially secure and technologically adept.

The biopharmaceutical contract manufacturing market is constrained by several factors, including small enterprises' lack of technological knowledge in biopharmaceutical manufacturing, abuse of patent sharing details, and easy reverse engineering of the drug composition formula. These factors drive pharma behemoths to build their production facilities, putting the efficacy of contract manufacturing firms at risk. In addition, the lack of intellectual property restrictions in many countries and unrestricted patent rights in others also hinder contract manufacturing companies' market growth.

This research report on the Europe Biopharmaceutical Contract Manufacturing Market has been segmented and sub-segmented into the following categories:

By Product Type:

  • Insulin
  • Monoclonal Antibodies
  • Growth Factors
  • Interferons
  • Recombinant Proteins
  • Vaccines
  • Others

By Therapeutic Area:

  • Infectious Disease
  • Cardiovascular Disease
  • Oncology
  • Metabolic Disease
  • Respiratory Disorder
  • Autoimmune Disease
  • Neurology
  • Ophthalmology
  • Others

By Application:

  • Commercial
  • Clinical

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the Europe held the second-largest share of the biopharmaceutical contract manufacturing market. The biopharmaceutical business in Europe is regulated by the European Medicines Agency and is subject to rigorous patent rights. The location has cutting-edge technologies for producing medications with maximum efficiency. Recommended new pharmaceuticals that enter the market after getting product clearance also significantly impact the market. The countries like Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe, are expected to contribute to the European biopharmaceutical contract manufacturing market.

In recent years, there has been a slew of new entrants into the field of CMOS. This has allowed the major pharmaceutical companies to lessen the burden of developing and manufacturing each new medicine on their own in the European biopharmaceutical contract manufacturing market.

Moreover, the major players in the region are implementing various strategies to gain a competitive advantage over the marketplace. The techniques include mergers, partnerships, and acquisitions. For instance, Sanofi has contracted Boehringer Ingelheim to manufacture its biologics program. In addition, many businesses are turning to CMOs to expedite the development process and reduce production expenses.

Rentschler, which is trying to expand globally, added a new facility to its Laupheim, Germany, plant two years ago to increase capacity, citing the increased need for biologics.

KEY MARKET PLAYERS

Key players operating in the Europe Biopharmaceutical contract manufacturing market profiled in this report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods      

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product Type                             

                                5.1.1 Introduction           

                                5.1.2 Insulin       

                                5.1.3 Monoclonal Antibodies     

                                5.1.4 Growth Factors     

                                5.1.5 Interferons             

                                5.1.6 Recombinant Protiens       

                                5.1.7 Vaccines   

                                5.1.8 Others      

                                5.1.9  Y-o-Y Growth Analysis, By Product Type   

                                5.1.10  Market Attractiveness Analysis, By Product Type               

                                5.1.11  Market Share Analysis, By Product Type

                5.2 Therapeutic Area                     

                                5.2.1 Introduction           

                                5.2.2 Infectious Disease               

                                5.2.3Cardiovascular Disease       

                                5.2.4 Oncology 

                                5.2.5 Metabolic Disease               

                                5.2.6 Respiratory Disorder           

                                5.2.7 Autoimmune Disease         

                                5.2.8 Neurology               

                                5.2.9 Ophthalmology     

                                5.2.10 Others    

                                5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area          

                                5.2.12 Market Attractiveness Analysis, By Therapeutic Area        

                                5.2.13 Market Share Analysis, By Therapeutic Area          

                5.3 Application                 

                                5.3.1 Introduction           

                                5.3.2 Clinical       

                                5.3.3 Commercial            

                                5.3.4 Y-o-Y Growth Analysis, By Application         

                                5.3.5 Market Attractiveness Analysis, By Application       

                                5.3.6 Market Share Analysis, By Application        

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product Type

                                                6.1.3.3 By Therapeutic Area

                                                6.1.3.4 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product Type

                                                6.1.4.3 By Therapeutic Area

                                                6.1.4.4 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product Type

                                                6.1.5.3 By Therapeutic Area

                                                6.1.5.4 By Application

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Patheon N.V.                             

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2Rentschler Biotechnologie GmbH                      

                 8.3 AbbVie Contract Manufacturing (An AbbVie Company)                        

                8.4 Biomeva GmbH                        

                8.5 Boehringer Ingelheim GmbH                              

                8.6 WuXi Biologics                           

                 8.7 Abzena Plc                 

                8.8 Lonza Group AG                       

                8.9 Samsung Biologics Co.                            

                8.10 Ajinomoto Althea, Inc.                        

                8.11 Fujifilm Diosynth Biotechnologies                  

                8.12 Probiogen AG                         

                8.13 Sandoz International GmbH                              

                8.14 KBI Biopharma, Inc.                              

                8.15 Baxter Biopharma Solutions                              

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                 

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Product Type, by  Therapeutic Area along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Europe Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  2. Europe Insulin Market By Region, From 2021 to 2026 ( USD Billion )
  3. Europe  Monoclonal Antibodies Market By Region, From 2021 to 2026 ( USD Billion )
  4. Europe  Growth Factors, Market By Region, From 2021 to 2026 ( USD Billion )
  5. Europe  Interferons Market By Region, From 2021 to 2026 ( USD Billion )
  6. Europe  Recombinant Proteins Market By Region, From 2021 to 2026 ( USD Billion )
  7. Europe Vaccines Market By Region, From 2021 to 2026 ( USD Billion )
  8. Europe  Others Market By Region, From 2021 to 2026 ( USD Billion )
  9. Europe Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  10. Europe Infectious Disease Market By Region, From 2021 to 2026 ( USD Billion )
  11. Europe  Cardiovascular Disease Market By Region, From 2021 to 2026 ( USD Billion )
  12. Europe Oncology Market By Region, From 2021 to 2026 ( USD Billion )
  13. Europe  Metabolic Disease Market By Region, From 2021 to 2026 ( USD Billion )
  14. Europe  Respiratory Disorder Market By Region, From 2021 to 2026 ( USD Billion )
  15. Europe  Autoimmune Disease Market By Region, From 2021 to 2026 ( USD Billion )
  16. Europe  Neurology Market By Region, From 2021 to 2026 ( USD Billion )
  17. Europe  Ophthalmology Market By Region, From 2021 to 2026 ( USD Billion )
  18. Europe  Others Market By Region, From 2021 to 2026 ( USD Billion )
  19. Europe Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )
  20. Europe Commercial  Market By Region, From 2021 to 2026 ( USD Billion )
  21. Europe  Clinical Market By Region, From 2021 to 2026 ( USD Billion )
  22. U.K. Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  23. U.K. Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  24. U.K. Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )
  25. Germany Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  26. Germany Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  27. Germany Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )
  28. France Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  29. France Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  30. France Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )
  31. Italy Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  32. Italy Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  33. Italy Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )
  34. Spain Bio Pharmaceutical Contract Manufacturing Market By Product Type , From 2021 to 2026 ( USD Billion )
  35. Spain Bio Pharmaceutical Contract Manufacturing Market By Therapeutic Area, From 2021 to 2026 ( USD Billion )
  36. Spain Bio Pharmaceutical Contract Manufacturing Market By Application, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample